Eletriptan
الیتریپتان
🧠 Nervous SystemTriptan (5-HT1B/1D agonist)
Market / country: 🇺🇸 USA
Relpax (US)
🧮 Dose calculator
Acute migraine attack · Regimen source: FDA Relpax · 2
- • If not resolved after 2 h or it returns, a second dose at least 2 h later; max 80 mg/day. FDA Relpax · 2
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⛔ Ischaemic coronary disease or coronary vasospasm (Prinzmetal); WPW or accessory-pathway arrhythmias; history of stroke, TIA or hemiplegic/basilar migraine; peripheral vascular disease; ischaemic bowel disease; uncontrolled hypertension; another triptan or ergot within 24 h; hypersensitivity. FDA Relpax · 4
- ⛔ Potent CYP3A4 inhibitors within 72 h: ketoconazole, itraconazole, nefazodone, clarithromycin, ritonavir, nelfinavir. FDA Relpax · 4
Warnings
- • Myocardial ischaemia and infarction; arrhythmias; chest/throat/jaw tightness; cerebrovascular events; medication-overuse headache; serotonin syndrome; increased blood pressure. FDA Relpax · 5
Formulations
- 20 mg tablet — tablet 🇺🇸 USA FDA Relpax · 3
- 40 mg tablet — tablet 🇺🇸 USA FDA Relpax · 3
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Relpax · 8.1
“Risk Summary Available human data on the use of RELPAX in pregnant women are not sufficient to draw conclusions about drug-associated risk for major birth defects and miscarriage.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Relpax · 8.2
“Risk Summary Eletriptan is excreted in human milk.”
- 👶 ChildrenSafety not established
Label: safety and effectiveness in children have not been established. FDA Relpax · 8.4
“Safety and effectiveness in pediatric patients have not been established.”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Relpax · 8.5
“Blood pressure was increased to a greater extent in elderly subjects than in young subjects.”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)NDA021016
- DailyMed (FDA label)FDA Relpax
- MedlinePlus (NIH)Eletriptan
- WHO ATC/DDDN02CC06
- Darooyab (Iran)Eletriptan
🇮🇷 Registered in Iran Darooyab · G-854/Eletriptan
Dosage forms with Iranian generic codes, per Darooyab.
- 08014 · ELETRIPTAN 20MG TAB · قرص التریپتان ۲۰ میلیگرم
- 08015 · ELETRIPTAN 40MG TAB · قرص التریپتان ۴۰ میلیگرم
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Relpax · 3FDA Relpax · 2FDA Relpax · 4FDA Relpax · 5FDA Relpax · SPL approval / marketing categoryFDA Relpax · 8.1FDA Relpax · 8.2FDA Relpax · 8.4FDA Relpax · 8.5
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-854/Eletriptan
- Clinical review⚠ Unverified